BACKGROUND: Induction therapy with alemtuzumab, followed by lower than conventional intensity post-transplant immunosuppression (eg, tacrolimus monotherapy), has been associated with reduced morbidity and mortality in abdominal and heart transplantation. We examined 5-year outcomes in lung recipients receiving alemtuzumab in conjunction with reduced-intensity post-transplant immunosuppression (early lower-dose tacrolimus; lower-dose steroids, with or without mycophenolate mofetil), compared with lung recipients receiving other induction agents or no induction in association with post-transplant immunosuppression. METHODS: A retrospective analysis was performed using prospectively collected data from a single-site clinical database of 336 lung recipients (aged ≥ 18) who received allografts between 1998 and 2005, classified by induction type: alemtuzumab, 127; Thymoglobulin, 43; daclizumab, 73; and none, 93. Survival analyses examined patient and graft survival, and freedom from acute cellular rejection (ACR), lymphocytic bronchiolitis, obliterative bronchiolitis (OB), bronchiolitis obliterans syndrome (BOS), and post-transplant lymphoproliferative disorder (PTLD). RESULTS: Five-year patient and graft survival differed by group (p = 0.046, p = 0.038, respectively). Alemtuzumab patient/graft survival rates were 59%/59%. Survival rates were 60%/44% for Thymoglobulin, 47%/46% for no induction, and 44%/41% for daclizumab. Freedom from ACR, lymphocytic bronchiolitis, OB, and BOS differed by group (all values, p < 0.008); alemtuzumab recipients showed greater 5-year freedom from each outcome (30%/82%/86%/54%) than Thymoglobulin (20%/54%/62%/27%), daclizumab (19%/55%/70%/43%), and no-induction groups (18%/70%/69%/46%). The groups did not differ in PTLD rates (≥ 94% free of PTLD at 5 years; p = 0.864). Effects were unchanged after controlling for potential covariates. CONCLUSIONS: Alemtuzumab induction may be associated with improved outcomes in lung transplantation. Randomized controlled trials are needed to establish any effects of this agent.
BACKGROUND: Induction therapy with alemtuzumab, followed by lower than conventional intensity post-transplant immunosuppression (eg, tacrolimus monotherapy), has been associated with reduced morbidity and mortality in abdominal and heart transplantation. We examined 5-year outcomes in lung recipients receiving alemtuzumab in conjunction with reduced-intensity post-transplant immunosuppression (early lower-dose tacrolimus; lower-dose steroids, with or without mycophenolate mofetil), compared with lung recipients receiving other induction agents or no induction in association with post-transplant immunosuppression. METHODS: A retrospective analysis was performed using prospectively collected data from a single-site clinical database of 336 lung recipients (aged ≥ 18) who received allografts between 1998 and 2005, classified by induction type: alemtuzumab, 127; Thymoglobulin, 43; daclizumab, 73; and none, 93. Survival analyses examined patient and graft survival, and freedom from acute cellular rejection (ACR), lymphocytic bronchiolitis, obliterative bronchiolitis (OB), bronchiolitis obliterans syndrome (BOS), and post-transplant lymphoproliferative disorder (PTLD). RESULTS: Five-year patient and graft survival differed by group (p = 0.046, p = 0.038, respectively). Alemtuzumabpatient/graft survival rates were 59%/59%. Survival rates were 60%/44% for Thymoglobulin, 47%/46% for no induction, and 44%/41% for daclizumab. Freedom from ACR, lymphocytic bronchiolitis, OB, and BOS differed by group (all values, p < 0.008); alemtuzumab recipients showed greater 5-year freedom from each outcome (30%/82%/86%/54%) than Thymoglobulin (20%/54%/62%/27%), daclizumab (19%/55%/70%/43%), and no-induction groups (18%/70%/69%/46%). The groups did not differ in PTLD rates (≥ 94% free of PTLD at 5 years; p = 0.864). Effects were unchanged after controlling for potential covariates. CONCLUSIONS:Alemtuzumab induction may be associated with improved outcomes in lung transplantation. Randomized controlled trials are needed to establish any effects of this agent.
Authors: Marc Estenne; Janet R Maurer; Annette Boehler; James J Egan; Adaani Frost; Marshall Hertz; George B Mallory; Gregory I Snell; Samuel Yousem Journal: J Heart Lung Transplant Date: 2002-03 Impact factor: 10.247
Authors: Jason D Christie; Leah B Edwards; Anna Y Kucheryavaya; Paul Aurora; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Josef Stehlik; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2010-10 Impact factor: 10.247
Authors: S A Yousem; G J Berry; P T Cagle; D Chamberlain; A N Husain; R H Hruban; A Marchevsky; N P Ohori; J Ritter; S Stewart; H D Tazelaar Journal: J Heart Lung Transplant Date: 1996-01 Impact factor: 10.247
Authors: Anthony P Khalifah; Ramsey R Hachem; Murali M Chakinala; Roger D Yusen; Aviva Aloush; G Alexander Patterson; Thalachallour Mohanakumar; Elbert P Trulock; Michael J Walter Journal: Am J Transplant Date: 2005-08 Impact factor: 8.086
Authors: A N Husain; M T Siddiqui; E W Holmes; A J Chandrasekhar; M McCabe; R Radvany; E R Garrity Journal: Am J Respir Crit Care Med Date: 1999-03 Impact factor: 21.405
Authors: Amadeo Marcos; Bijan Eghtesad; John J Fung; Paulo Fontes; Kusum Patel; Michael Devera; Wallis Marsh; Timothy Gayowski; Anthony J Demetris; Edward A Gray; Bridget Flynn; Adriana Zeevi; Noriko Murase; Thomas E Starzl Journal: Transplantation Date: 2004-10-15 Impact factor: 4.939
Authors: Peter M Hopkins; Christina L Aboyoun; Prashant N Chhajed; Monique A Malouf; Marshall L Plit; Stephen P Rainer; Allan R Glanville Journal: Am J Respir Crit Care Med Date: 2004-08-05 Impact factor: 21.405
Authors: Allan D Kirk; Douglas A Hale; Roslyn B Mannon; David E Kleiner; Steven C Hoffmann; Robert L Kampen; Linda K Cendales; Douglas K Tadaki; David M Harlan; S John Swanson Journal: Transplantation Date: 2003-07-15 Impact factor: 4.939
Authors: Andreas G Tzakis; Panagiotis Tryphonopoulos; Tomoaki Kato; Seigo Nishida; David M Levi; Juan R Madariaga; Jeffrey J Gaynor; Werviston De Faria; Arie Regev; Violet Esquenazi; Debbie Weppler; Phillip Ruiz; Joshua Miller Journal: Transplantation Date: 2004-04-27 Impact factor: 4.939
Authors: Stuart J Knechtle; John D Pirsch; John H Fechner; Bryan N Becker; Andreas Friedl; Robert B Colvin; Lauralynn K Lebeck; L Thomas Chin; Yolanda T Becker; Jon S Odorico; Anthony M D'Alessandro; Munci Kalayoglu; Majed M Hamawy; Huaizhong Hu; Debra D Bloom; Hans W Sollinger Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086
Authors: Shahid Husain; Mariangela R Resende; Nimerta Rajwans; Ricardo Zamel; Joseph M Pilewski; Maria M Crespo; Lianne G Singer; Kenneth R McCurry; Jay K Kolls; Shaf Keshavjee; W Conrad Liles Journal: Transplantation Date: 2014-01-15 Impact factor: 4.939
Authors: Carlo J Iasella; Spencer A Winters; Abigail Kois; Jaehee Cho; Stefanie J Hannan; Ritchie Koshy; Cody A Moore; Christopher R Ensor; Elizabeth A Lendermon; Matthew R Morrell; Joseph M Pilewski; Pablo G Sanchez; Daniel J Kass; Jonathan K Alder; S Mehdi Nouraie; John F McDyer Journal: Am J Transplant Date: 2020-01-22 Impact factor: 8.086
Authors: Emily M Rosenberger; Andrea F DiMartini; Annette J DeVito Dabbs; Christian A Bermudez; Joseph M Pilewski; Yoshiya Toyoda; Mary Amanda Dew Journal: Transplantation Date: 2016-01 Impact factor: 4.939
Authors: S Samuel Weigt; Ariss DerHovanessian; W Dean Wallace; Joseph P Lynch; John A Belperio Journal: Semin Respir Crit Care Med Date: 2013-07-02 Impact factor: 3.119